Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

被引:215
作者
Grundy, SM
机构
[1] Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Clin Nutr, Dallas, TX 75390 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1038/nrd2005
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The metabolic syndrome-a collection of factors associated with increased risk for cardiovascular disease and diabetes-is becoming increasingly common, largely as a result of the increase in the prevalence of obesity. Although it is generally agreed that first-line clinical intervention for the metabolic syndrome is lifestyle change, this is insufficient to normalize the risk factors in many patients, and so residual risk could be high enough to justify drug therapy. However, at present there are no approved drugs that can reliably reduce all of the metabolic risk factors over the long term, and so there is growing interest in therapeutic strategies that might target multiple risk factors more effectively, thereby minimizing problems with polypharmacy. This review summarizes current understanding of the nature of the metabolic syndrome, and discusses each of the risk factors of the metabolic syndrome as possible primary drug targets; potential secondary or tertiary targets are also considered.
引用
收藏
页码:294 / 309
页数:15
相关论文
共 129 条
[61]   Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia [J].
Law, RE ;
Meehan, WP ;
Xi, XP ;
Graf, K ;
Wuthrich, DA ;
Coats, W ;
Faxon, D ;
Hsueh, WA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (08) :1897-1905
[62]   HDL as a target in the treatment of atherosclerotic cardiovascular disease [J].
Linsel-Nitschke, P ;
Tall, AR .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) :193-205
[64]   EFFECT OF ANTIHYPERTENSIVE DRUGS ON INSULIN, GLUCOSE, AND LIPID-METABOLISM [J].
LITHELL, HOL .
DIABETES CARE, 1991, 14 (03) :203-209
[65]   Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis [J].
Lonn E. .
Current Atherosclerosis Reports, 2002, 4 (5) :363-372
[66]   Peroxisome proliferator-activated receptor δ controls muscle development and oxydative capability [J].
Luquet, S ;
Lopez-Soriano, J ;
Holst, D ;
Fredenrich, A ;
Melki, J ;
Rassoulzadegan, M ;
Grimaldi, PA .
FASEB JOURNAL, 2003, 17 (13) :2299-+
[67]   Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults [J].
Malik, S ;
Wong, ND ;
Franklin, SS ;
Kamath, TV ;
L'Italien, GJ ;
Pio, JR ;
Williams, GR .
CIRCULATION, 2004, 110 (10) :1245-1250
[68]  
Marx N, 2001, CIRCULATION, V103, P213
[69]  
Matsuzawa Yuji, 2005, Semin Vasc Med, V5, P34, DOI 10.1055/s-2005-871744
[70]   The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study [J].
McNeill, AM ;
Schmidt, MI ;
Rosamond, WD ;
East, HE ;
Girman, CJ ;
Ballantyne, CM ;
Golden, SH ;
Heiss, G .
DIABETES CARE, 2005, 28 (02) :385-390